Lataa...
New agents on the horizon in hepatocellular carcinoma
Despite the successful approval and extensive application of sorafenib, the prognosis for patients with advanced hepatocellular carcinoma (HCC) remains poor. Fortunately, there have been renewed and continued interests and active research in developing other molecularly targeted agents in HCC during...
Tallennettuna:
| Päätekijä: | |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
SAGE Publications
2013
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3539273/ https://ncbi.nlm.nih.gov/pubmed/23323146 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834012458480 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|